<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">systhiper-329</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КАРДИОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CARDIOLOGY</subject></subj-group></article-categories><title-group><article-title>Значение вариабельности артериального давления в клинической практике. Возможности амлодипина в снижении внутривизитной вариабельности артериального давления (по результатам российской программы «ВАРИАЦИЯ»)</article-title><trans-title-group xml:lang="en"><trans-title>The value of blood pressure variability in clinical practice. Opportunities of amlodipine in reducing blood pressure variability (based on the Russian program «VARIATIONS»)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Остроумова</surname><given-names>О. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ostroumova</surname><given-names>O. D.</given-names></name></name-alternatives><email xlink:type="simple">ostroumova.olga@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бондарец</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bondarets</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусева</surname><given-names>Т. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Guseva</surname><given-names>T. F.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России; ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России</institution><country>Russian Federation</country></aff><aff xml:lang="ru" id="aff-2"><institution>ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2022</year></pub-date><volume>11</volume><issue>1</issue><fpage>11</fpage><lpage>16</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Остроумова О.Д., Бондарец О.В., Гусева Т.Ф., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Остроумова О.Д., Бондарец О.В., Гусева Т.Ф.</copyright-holder><copyright-holder xml:lang="en">Ostroumova O.D., Bondarets O.V., Guseva T.F.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/329">https://www.syst-hypertension.ru/jour/article/view/329</self-uri><abstract><p>В статье рассмотрено значение разных видов вариабельности артериального давления (АД) как независимого фактора риска развития инсульта и инфаркта миокарда при артериальной гипертонии. Приведены результаты российской наблюдательной программы (1500 пациентов) о влиянии терапии амлодипином на внутривизитную вариабельность АД в условиях реальной клинической практики. Согласно полученным результатам, амлодипин в дозе 5-10 мг уже через 1 мес лечения достоверно снижает внутривизитную вариабельность систолического и диастолического АД у лиц обоего пола. Его влияние на краткосрочную вариабельность диастолического АД имеет дозозависимый характер.</p></abstract><trans-abstract xml:lang="en"><p>The article discusses the importance of different types of variability in blood pressure (BP) as an independent risk factor for stroke and myocardial infarction in patients with arterial hypertension. The results of the Russian observation program (1500 patients) on the impact of amlodipine show BP variability in real clinical practice. According to the results, amlodipine 5-10 mg after 2 weeks of treatment significantly reduces the variability of systolic and diastolic blood pressure in both sexes. His influence on the short-term variability in diastolic blood pressure is dose-dependent.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>вариабельность артериального давления</kwd><kwd>артериальная гипертония</kwd><kwd>антигипертензивная терапия</kwd><kwd>антагонисты кальция</kwd><kwd>амлодипин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>variability of blood pressure</kwd><kwd>hypertension</kwd><kwd>antihypertensive therapy</kwd><kwd>calcium antagonists</kwd><kwd>amlodipine</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rothwell P.M, Howard S.C, Dolan E et al. Prognostic significance of visit - to - visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.</mixed-citation><mixed-citation xml:lang="en">Rothwell P.M, Howard S.C, Dolan E et al. Prognostic significance of visit - to - visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sever P.S, Dahlof B, Poulter N.R et al. Rationale, design, methods and baseline demography of participants of the Anglo- Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 6: 1139-47.</mixed-citation><mixed-citation xml:lang="en">Sever P.S, Dahlof B, Poulter N.R et al. Rationale, design, methods and baseline demography of participants of the Anglo- Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 6: 1139-47.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentral randomized controlled trial. Lancet 2005; 366: 895-906.</mixed-citation><mixed-citation xml:lang="en">Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentral randomized controlled trial. Lancet 2005; 366: 895-906.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Webb A.J.S, Fischer U, Mehta Z, Rothwell P.M. Effects of antihypertensive - drug class on interindividual variation in BP and risk of stroke: a systematic review and meta - analysis. Lancet 2010; 375: 906-15.</mixed-citation><mixed-citation xml:lang="en">Webb A.J.S, Fischer U, Mehta Z, Rothwell P.M. Effects of antihypertensive - drug class on interindividual variation in BP and risk of stroke: a systematic review and meta - analysis. Lancet 2010; 375: 906-15.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rothwell P.M, Webb A.J.S. Effect of Dose and Combination of Antihypertensives on Interindividual Blood Pressure Variability: A Systematic Review. Stroke 2011; 42: 2860-5.</mixed-citation><mixed-citation xml:lang="en">Rothwell P.M, Webb A.J.S. Effect of Dose and Combination of Antihypertensives on Interindividual Blood Pressure Variability: A Systematic Review. Stroke 2011; 42: 2860-5.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Диагностика и лечение артериальной гипертензии. Российский рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 5-26.</mixed-citation><mixed-citation xml:lang="en">Диагностика и лечение артериальной гипертензии. Российский рекомендации (четвертый пересмотр). Системные гипертензии. 2010; 3: 5-26.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
